BG-75202

Phase 1Small molecule

BBeOne Medicines

BG-75202 is one of 27 small molecule programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 4

Vfend

PPrism Pharmaceuticals

Preclinical

—5

Ablavar

LLantheus Medical Imaging

Preclinical

2 6

BG-75202

BBeOne Medicines

Phase 1

1 7

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 8

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Myeloid Malignancy

NCT07619287

Q1 2037

Phase 1Recruiting

Breast Cancer

NCT07222267

Clinical

Trials by Indication[1]

Myeloid Malignancy1 trial

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies

Recruiting·BBeOne Medicines·Phase 1·NCT07619287·118 enrolled

Breast Cancer1 trial

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Recruiting·BBeOne Medicines·Phase 1·NCT07222267·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BG-75202. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BG-75202 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BG-75202. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeOne Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBeOne Medicines

BG-75202

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2037

Trials by Indication[1]

Myeloid Malignancy1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News